The FDA inspection confirmed BRG’s commitment to quality and compliance, which strengthens the confidence of our existing sponsors and serves as an invitation to future collaborations.
This outcome highlights the expertise and dedication of our entire team, whose professionalism and attention to detail ensure the highest industry standards every day.
We extend our gratitude to our colleagues across BRG for their outstanding work, and to our Principal Investigator, Dr. Katarzyna Jarus-Dziedzic, whose extensive clinical experience and leadership have been instrumental in shaping BRG’s reputation for reliable, high-quality research.
Our mission goes beyond compliance — we are committed to delivering top-tier Phase 1 research that supports our partners in developing tomorrow’s medicines. We also recognize the FDA inspectors for their thorough and constructive approach, which provided valuable perspectives for our continuous improvement journey.
At BRG, we remain dedicated to excellence, innovation, and trusted partnerships in early-phase clinical research.